McKesson stock steadies after cybersecurity filing and $9.93 EPS
Published on 08/29/2026 at 14:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
McKesson Corp. (ISIN US58155Q1031) is trading with a new regulatory overhang after a cybersecurity incident disclosed for August 25, 2026, while the latest quarterly report showed $9.93 in EPS on $105.38 billion in revenue. Shares opened at $895.59 on the latest session, with a 52-week range of $679.65 to $999.00 and a market value of $104.42 billion.
The filing says the incident was discovered on August 25, 2026 and that the investigation is in its early stages, with no determination yet that it is material or likely to have a material impact. That keeps the market's near-term attention on execution and disclosure discipline as much as on the core distribution business.
Latest quarter still sets the tone
The August 5, 2026 earnings report remains the most recent full operating snapshot in play: EPS of $9.93 beat the $9.56 consensus by $0.37, and revenue of $105.38 billion came in ahead of $103.88 billion in estimates. Revenue rose 7.7% from $97.82 billion a year earlier, while net margin was 1.12%.
That combination matters because the company is still converting scale into steady earnings growth, even as the margin profile stays thin for a distributor. On MarketBeat, analysts currently show a consensus target of $973.44 and a consensus rating of Moderate Buy, which sits above the latest quoted price level.
Market level and guidance
MarketBeat also lists McKesson's FY 2027 guidance at 44.200 to 45.000 EPS, a range that frames the next valuation debate after the August 5 results. Against that outlook, the stock's 12-month high of $999.00 leaves room for further upside, but the fresh filing now adds a separate risk variable.
The move from $8.26 in EPS a year earlier to $9.93 in the latest quarter gives investors a clear comparison point. The bigger question is whether the current reporting cycle can keep that pace while the cybersecurity review runs in the background.
Oncology and specialty care
McKesson's business spans pharmaceutical distribution, specialty pharmacy, medical-surgical supply, and health care technology services. In that mix, oncology and specialty care remain important because they tend to carry higher strategic weight than the core wholesale channel.
One example is Precision Medicine Group, which McKesson said it will acquire for $2.25 billion, a deal that points toward deeper exposure to oncology and related services. That fits the broader pattern of pushing into higher-growth healthcare services while the distribution base keeps the cash flow engine running.
Price at the latest session
McKesson stock opened at $895.59 on the latest session, with the share price sitting between a 12-month low of $679.65 and a 12-month high of $999.00. The market cap was $104.42 billion.
Company details
Company: McKesson Corp.
ISIN: US58155Q1031
Ticker: MCK
Exchange: NYSE
Price (as of August 28, 2026, 1:35 p.m. ET): $894.65 USD
Market cap: $104.42 billion
Sector / Industry: Health Care / Healthcare Distributors
Index membership: S&P 500
